Wall Street Zen downgraded shares of Aardvark Therapeutics (NASDAQ:AARD – Free Report) from a sell rating to a strong sell rating in a research report report published on Saturday morning,Wall Street Zen reports.
Other equities research analysts have also recently issued research reports about the stock. Royal Bank Of Canada set a $2.50 target price on shares of Aardvark Therapeutics in a research note on Friday, October 23rd. Raymond James Financial reiterated a “market perform” rating on shares of Aardvark Therapeutics in a research report on Friday. UBS Group set a $4.00 target price on shares of Aardvark Therapeutics in a research report on Monday, October 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aardvark Therapeutics in a research note on Tuesday, September 29th. Finally, HC Wainwright lowered their price target on shares of Aardvark Therapeutics from $4.00 to $2.00 and set a “hold” rating on the stock in a research report on Monday, October 26th. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $11.56.
View Our Latest Research Report on AARD
Aardvark Therapeutics Stock Performance
Shares of NASDAQ:AARD traded down $0.19 during trading on Friday, reaching $1.33. The stock had a trading volume of 402,447 shares, compared to its average volume of 1,698,199. The business has a fifty day moving average price of $3.76 and a 200-day moving average price of $5.72. The stock has a market cap of $29.10 million, a PE ratio of -0.41 and a beta of 4.38. Aardvark Therapeutics has a 1-year low of $0.93 and a 1-year high of $16.60.
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.19). Sell-side analysts expect that Aardvark Therapeutics will post -3.05 earnings per share for the current year.
Insider Activity at Aardvark Therapeutics
In related news, insider Nelson Sun sold 62,000 shares of Aardvark Therapeutics stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $5.18, for a total transaction of $321,160.00. Following the transaction, the insider owned 35,475 shares in the company, valued at approximately $183,760.50. This trade represents a 63.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 17.80% of the company’s stock.
Institutional Trading of Aardvark Therapeutics
Several large investors have recently added to or reduced their stakes in AARD. BlackRock Inc. acquired a new stake in Aardvark Therapeutics during the second quarter worth about $1,077,000. Marshall Wace LLP raised its stake in Aardvark Therapeutics by 593.0% during the third quarter. Marshall Wace LLP now owns 132,204 shares of the company’s stock worth $697,000 after purchasing an additional 113,128 shares during the period. Renaissance Technologies LLC acquired a new position in Aardvark Therapeutics in the 1st quarter valued at about $267,000. J. Goldman & Co LP acquired a new position in Aardvark Therapeutics in the 2nd quarter valued at about $233,000. Finally, Ieq Capital LLC acquired a new position in Aardvark Therapeutics in the 2nd quarter valued at about $221,000.
Aardvark Therapeutics Company Profile
Aardvark Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops oral medicines for metabolic disorders, with a focus on conditions involving excessive hunger and disrupted energy balance. The company’s lead candidate, ARD-101, is an investigational oral therapy designed to activate bitter taste receptors in the gut and influence gut-brain signaling. Aardvark has studied the candidate for hyperphagia, or excessive hunger, associated with Prader-Willi syndrome and hypothalamic obesity.
Recommended Stories
- Five stocks we like better than Aardvark Therapeutics
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
